Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Payables (2020 - 2025)

Maxcyte (MXCT) has disclosed Payables for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Payables rose 3.17% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 3.17% year-over-year, with the annual reading at $1.4 million for FY2025, 3.17% up from the prior year.
  • Payables for Q4 2025 was $1.4 million at Maxcyte, up from $1.3 million in the prior quarter.
  • The five-year high for Payables was $4.4 million in Q1 2022, with the low at $292000.0 in Q4 2022.
  • Average Payables over 5 years is $1.6 million, with a median of $1.4 million recorded in 2025.
  • The sharpest move saw Payables plummeted 83.96% in 2022, then skyrocketed 317.6% in 2024.
  • Over 5 years, Payables stood at $1.8 million in 2021, then tumbled by 83.96% to $292000.0 in 2022, then surged by 154.45% to $743000.0 in 2023, then surged by 82.77% to $1.4 million in 2024, then grew by 3.17% to $1.4 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $1.4 million, $1.3 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.